Effect of spironolactone on transmitral diastolic blood flow and course of chronic heart failure with preserved left ventricular ejection fraction
DOI:
https://doi.org/10.14739/2310-1210.2015.5.53746Keywords:
Congestive Heart Failure, Spironolactone, NT-proBNPAbstract
Existing recommendations on the mineralocorticoid/aldosterone receptor antagonists have been developed only for patients with systolic heart failure, and all outcome trials performed in patients with preserved ejection fraction failed to improve prognosis in this condition.
Аim. To examine the effectiveness of spironolactone therapy in elderly patients with chronic heart failure NYHA I–II with preserved left ventricular ejection fraction.
Methods and results. Peculiarities of transmitral diastolic blood flow was studied with Doppler echocardiography. 6-min walk test and NT-proBNP was performed for the assessment of clinical course improvement in such patients.
Conclusion. It was found that spironolactone therapy improves mitral diastolic blood flow, reduces concentration of NT-proBNP, which correlates with improved clinical course of heart failure.
References
Mosterd, A., & Hoes, A. W. (2007) Clinical epidemiology of heart failure. Heart, 93, 1137–1146. doi:10.1136/hrt.2003.025270.
McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 33(14), 1787–1847. doi: 10.1093/eurheartj/ehs104.
Owan, T. E., Hodge, Do., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med, 355, 251–259. doi: 10.1056/NEJMoa052256.
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., et al. (2006) Outcome of heart failure with preserved ejection in a population-based study. N Engl J Med, 355, 260–269. doi:10.1056/NEJMoa051530.
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data metaanalysis. Eur Heart J, 33, 1750–1757. doi: 10.1093/eurheartj/ehr254.
Cleland, J. G., & Pellicori, P. (2013) Defining diastolic heart failure and identifying effective therapies. JAMA, 309(8), 825–826. doi: 10.1001/jama.2013.1569.
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 362, 777–781.
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., et al. (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med, 359, 2456–2467. doi: 10.1056/NEJMoa0805450.
Cleland, J. G., Tendera, M., Adamus, J., Freemantle, N., Polonski, L., & Taylor, J. (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J, 27, 2338–2345. doi:10.1093/eurheartj/ehl250.
Ingle, L., Shelton, R. J., Rigby, A. S., Nabb, S., Clark, A. L., & Cleland, J. G. F. (2005) The reproducibility and sensutivity of the 6-min walk-test in elderly patients with chronic heart failure. Eur Heart J, 26, 1742–1751. doi:10.1093/eurheartj/ehi259.
Devereux, R. B., Alonso, D., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol, 57, 450–458.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)